ZIOPHARM Oncology, Inc. (ZIOP) Reaches $4.37 After 6.00% Down Move; Profile of 1 Analysts Covering Boise Cascade Company (BCC)

March 14, 2018 - By Winifred Garcia

The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is a huge mover today! The stock decreased 1.50% or $0.0664 during the last trading session, reaching $4.3736. About 550,929 shares traded. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since March 14, 2017 and is uptrending. It has underperformed by 14.95% the S&P500.The move comes after 8 months negative chart setup for the $616.58 million company. It was reported on Mar, 14 by Barchart.com. We have $4.11 PT which if reached, will make NASDAQ:ZIOP worth $36.99 million less.

Among 6 analysts covering Boise Cascade (NYSE:BCC), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Boise Cascade had 18 analyst reports since July 24, 2015 according to SRatingsIntel. As per Wednesday, October 11, the company rating was maintained by BMO Capital Markets. The firm has “Outperform” rating by BMO Capital Markets given on Friday, February 19. The stock of Boise Cascade Company (NYSE:BCC) has “Hold” rating given on Thursday, April 13 by BMO Capital Markets. The firm earned “Hold” rating on Wednesday, October 4 by Vertical Research. As per Friday, July 24, the company rating was upgraded by DA Davidson. Goldman Sachs initiated the shares of BCC in report on Thursday, September 22 with “Buy” rating. The firm has “Neutral” rating by Bank of America given on Wednesday, January 24. The firm has “Hold” rating given on Friday, June 9 by BMO Capital Markets. As per Wednesday, October 26, the company rating was downgraded by Goldman Sachs. The company was downgraded on Monday, October 2 by Bank of America. See Boise Cascade Company (NYSE:BCC) latest ratings:

25/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $36.0 Maintain
24/01/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $44 New Target: $46 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $33.0 Maintain
04/10/2017 Broker: Vertical Research Old Rating: Buy New Rating: Hold Downgrade
03/10/2017 Broker: DA Davidson Old Rating: Buy New Rating: Neutral Downgrade
02/10/2017 Broker: Bank of America Rating: Hold New Target: $36.0 Downgrade
15/09/2017 Broker: Sidoti Rating: Buy New Target: $50.0 Initiate

Boise Cascade Company manufactures wood products and distributes building materials in the United States and Canada. The company has market cap of $1.57 billion. The Company’s Wood Products segment makes laminated veneer lumber and laminated beams used in headers and beams; I-joists for residential and commercial flooring and roofing systems, and other structural applications; structural, appearance, and industrial plywood panels; and ponderosa pine lumber, studs, and particleboards. It has a 19.16 P/E ratio. This segmentÂ’s products are used primarily in new residential construction, residential repair-and-remodeling markets, and light commercial construction.

Since March 5, 2018, it had 0 insider buys, and 1 sale for $257,441 activity. SAHLBERG JOHN T. had sold 6,582 shares worth $257,441.

Investors sentiment decreased to 1.43 in Q3 2017. Its down 0.16, from 1.59 in 2017Q2. It dropped, as 11 investors sold Boise Cascade Company shares while 52 reduced holdings. 41 funds opened positions while 59 raised stakes. 35.14 million shares or 3.78% less from 36.52 million shares in 2017Q2 were reported. Prelude Mngmt Llc holds 0% or 600 shares in its portfolio. Schwab Charles Inv Management Inc reported 432,488 shares. Louisiana State Employees Retirement Systems has 15,600 shares for 0.03% of their portfolio. Bogle Investment Lp De stated it has 0.09% of its portfolio in Boise Cascade Company (NYSE:BCC). 22,500 are held by Balyasny Asset Mgmt Lc. Nationwide Fund Advsr invested in 0.01% or 72,777 shares. 701,408 were accumulated by Retail Bank Of America De. State Of Alaska Department Of Revenue stated it has 7,628 shares. Penn Cap Mngmt owns 0.02% invested in Boise Cascade Company (NYSE:BCC) for 9,140 shares. Parkside State Bank invested in 0% or 33 shares. 8,700 are held by Duncker Streett. Paloma Partners holds 0% or 8,910 shares. Acadian Asset Mgmt Limited Liability stated it has 0% in Boise Cascade Company (NYSE:BCC). Barclays Plc owns 0% invested in Boise Cascade Company (NYSE:BCC) for 65,937 shares. Northern Tru Corporation holds 0.01% of its portfolio in Boise Cascade Company (NYSE:BCC) for 817,915 shares.

The stock decreased 0.43% or $0.17 during the last trading session, reaching $40.62. About 99,197 shares traded. Boise Cascade Company (NYSE:BCC) has risen 24.71% since March 14, 2017 and is uptrending. It has outperformed by 8.01% the S&P500.

Analysts await ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings on May, 7. They expect $-0.13 earnings per share, up 13.33% or $0.02 from last year’s $-0.15 per share. After $-0.13 actual earnings per share reported by ZIOPHARM Oncology, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $616.58 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 9 analyst reports since December 4, 2015 according to SRatingsIntel. The rating was upgraded by Wells Fargo on Wednesday, August 10 to “Market Perform”. The company was initiated on Friday, December 4 by Wells Fargo. As per Wednesday, May 11, the company rating was maintained by Mizuho. The rating was maintained by Mizuho with “Neutral” on Monday, January 25. The rating was maintained by H.C. Wainwright with “Buy” on Monday, March 5. The firm has “Market Perform” rating given on Thursday, June 2 by Raymond James. H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on Thursday, December 14 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.